Carbidopa monohydrate
In Stock•Starting at $8 for 1 g•Purity ≥ 97%
| CAS No. | 38821-49-7 |
|---|---|
| MDL No. | MFCD00889211 |
| MF | C10H16N2O5 |
| MW | 244.24 |
| InChI Key | QTAOMKOIBXZKND-PPHPATTJSA-N |
Pricing & Availability
| Pack Size | Purity | Price | Availability | Action |
|---|---|---|---|---|
| 1 g | 97% | $8 | In Stock | |
| 5 g | 97% | $21 | In Stock | |
| 25 g | 97% | $65 | In Stock | |
| 100 g | 97% | $207 | In Stock | |
| Custom synthesis and bulk supply options are available upon request. | ||||
Product Information
Carbidopa is the hydrate of 3-(3,4-dihydroxyphenyl)propanoic acid with the hydrogens alpha to the carboxyl group substituted by hydrazinyl and methyl groups (S-configuration). It is a dopa decarboxylase inhibitor that prevents the conversion of levodopa to dopamine. Although it has no antiparkinson activity by itself, it is used in Parkinson's disease management to reduce peripheral adverse effects of levodopa. It functions as an inhibitor of EC 4.1.1.28 (aromatic-L-amino-acid decarboxylase), an antiparkinson drug, a dopaminergic agent, and an antidyskinesia agent. It belongs to hydrazines, hydrates, monocarboxylic acids, and catechols, and contains anhydrous carbidopa.
| CAS No. | 38821-49-7 |
|---|---|
| Product Name | Carbidopa monohydrate |
Biological Targets
DDC
Associated Conditions
albinism·injury·multiple sclerosis·Angelman syndrome·Riley-Day syndrome·
* The information provided here is compiled from public sources and is for reference only.
